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Abstract The significant increase of the linezolid-resistant en-
terococci (LRE) has been observed in Polish hospitals since
2012 and our study aimed at elucidating the possible reasons
for this phenomenon. Polish LRE isolates were analysed by
multilocus-sequence typing (MLST) and multiple locus
variable-number tandem repeat (VNTR) analysis (MLVA), po-
lymerase chain reaction (PCR) and PCR-restriction fragment
length polymorphism (PCR-RFLP) to establish clonal related-
ness and mechanism of linezolid resistance, respectively. Fifty
analysed LRE (2008–2015) included mostly Enterococcus
faecium (82%) and Enterococcus faecalis (16%).
Enterococcus faecium belonged to the hospital-adapted lineages
17/18 and 78, while E. faecalis isolates represented ST6, a
hospital-associated type, and ST116, found in both humans
and food-production animals. The G2576T 23S rRNAmutation
was the most frequent (94%) mechanism of linezolid/tedizolid
resistance of LRE. None of the isolates carried the plasmid-
associated gene of Cfr methyltransferase, whereas optrA,
encoding the ABC-type drug transporter, was identified in two
E. faecalis isolates. In these isolates, optrA was located on a
plasmid, transferable to both E. faecium and E. faecalis, whose
partial (36.3 kb) sequence was 100% identical to the pE394
plasmid, identified previously in China in both clinical and farm
animal isolates. The optrA–E. faecium transconjugant displayed
a significant growth deficiency, in contrast to the optrA–
E. faecalis. Our study indicates the role of mutation acquisition
by hospital-adapted clones of enterococci as a major driver of
increasing resistance to linezolid and tedizolid. Transferability
and apparent lack of a biological cost of resistance suggest that
E. faecalis may be a natural reservoir of optrA, an emerging
mechanism of oxazolidinone resistance.
Introduction
Although enterococci represent generally harmless commen-
sals of humans and animals, they have recently become a
common cause of hospital-associated infections (HAIs). The
majority of enterococcal HAIs are caused by high-risk entero-
coccal clonal complexes (HiRECCs) of the two clinically rel-
evant species, Enterococcus faecalis and Enterococcus
faecium. HiRECCs of E. faecalis include clonal complexes
(CCs) 6 (also known as CC2), 9 and 87 significantly over-
represented among hospital strains [1, 2]. Almost all clinical
isolates of E. faecium were initially included in CC17, subse-
quently divided into lineages 17, 18 and 78 [3]. The Bayesian
analysis of population structure (BAPS) clustered nosocomial
isolates into two groups, BAPS 2-1 and BAPS 3-3, corre-
sponding to lineages 78 and 17/18, respectively [4].
The increasing prevalence of enterococci, resistant to im-
portant anti-enterococcal drugs, such as aminoglycosides and
glycopeptides, currently represents a great challenge for clini-
cians. Linezolid was the first antimicrobial agent of the class
of oxazolidinones introduced to clinical use to treat infections
caused by multidrug-resistant aerobic Gram-positive bacteria,
including vancomycin-resistant enterococci (VRE) [5].
Parts of the study results were presented at the 24th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona,
Spain, 10–13 May 2014.
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Linezolid inhibits protein synthesis by binding the central
loop of domain V in the 23S rRNA in bacterial ribosome [6]
and in enterococci, the G2576T (Escherichia coli numbering)
mutation in the 23S rRNA gene(s) was, thus far, the predom-
inant mechanisms responsible for the loss of susceptibility to
this compound. Other mechanisms of linezolid resistance in-
clude methylation of the A2503 residue in 23S rRNA by the
Cfr methyltransferase and mutations in the L3 and L4 ribo-
somal proteins (reviewed recently in [7]). Recently, an efflux
mechanism of resistance to oxazolidinones and phenicols was
found in bothE. faecalis and E. faecium [8], determined by the
plasmid-borne optrA gene, responsible for the production of
the ABC-type transporter OptrA.
Linezolid-resistant enterococci (LRE) as hospital alert
pathogens are collected by the National Reference Centre for
Susceptibility Testing (NRCST), located at the National
Medicines Institute inWarsaw, Poland. Since 2012, LRE have
been increasingly reported to the NRCST. Thus, we per-
formed a study with the aim to characterise recent Polish clin-
ical isolates of LRE with respect to their species composition,
susceptibility phenotypes to other antimicrobials, mechanisms
of linezolid resistance and clonal relatedness. The prevalence
of optrA, its genetic environment, transferability and associat-
ed fitness cost were of our special interest due to their rele-
vance for the spread of linezolid resistance in enterococci. To
our knowledge, this is the first report of such data for LRE
from Central-Eastern Europe and one of a very few showing
the importance of the transferable optrA determinant.
Materials and methods
Species identification, antimicrobial susceptibility testing
and analysis of vancomycin resistance determinants
Fifty clinical LRE isolates (one isolate per patient) were collect-
ed by the NRCST during the period from September 2008 till
the end of December 2015 in passive surveillance. The isolates
were obtained from 20 hospital settings, located in 12 Polish
cities (Supplementary Fig. A1). Species identification was per-
formed using standard microbiological methods and, for
Enterococcus avium, by multilocus sequence analysis (MLSA)
[9]. Total DNA was extracted using Genomic DNA Prep Plus
(A&A Biotechnology, Gdynia, Poland). Isolates were stored at
−80 °C until further analysis. Antimicrobial susceptibility of the
isolates to daptomycin and tedizolid was evaluated with the use
of stripes with predefined antibiotic concentrations (bioMérieux,
Marcy-l’Etoile, France and Liofilchem, Roseto degli Abruzzi,
Italy, respectively) and for the remaining antimicrobials
(Table 1) by the broth microdilution method, according to the
Clinical and Laboratory Standards Institute (CLSI) guidelines,
using reference strains E. faecalis ATCC 29212 and
Staphylococcus aureus ATCC 29213 as quality controls.
Minimum inhibitory concentration (MIC) interpretation was
conducted according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) or CLSI clini-
cal breakpoints (when EUCAST breakpoints were not avail-
able) and the clinical breakpoint for tedizolid for E. faecalis
Table 1 Antimicrobial
susceptibility of Polish linezolid-
resistant Enterococcus faecium
and Enterococcus faecalis
Antimicrobial agent/phenotype E. faecium E. faecalis
R (%) MIC50 MIC90 R (%) MIC50 MIC90
Linezolid 41 (100) 16 64 8 (100) 16 32
Tedizolid 41 (100) 4 >32 8 (100) 4 16
Penicillin 41 (100) 256 >256 1 (12.5) 4 16
Ampicillin 41 (100) 256 >256 0 0.5 1.0
HLGR 33 (80.5) >1024 >1024 7 (87.5) >1024 >1024
HLSR 31 (75.6) 2048 >2048 8 (100) >2048 >2048
Vancomycin 37 (90.2) >256 >256 0 2.0 4.0
Teicoplanin 34 (82.9) 64 256 0 0.25 0.5
Tetracycline 12 (29.3) 0.25 32 8 (100) 64 128
Erythromycin 31 (75.6) 256 >256 8 (100) >256 >256
Tigecycline 0 0.25 0.25 0 0.25 0.25
Ciprofloxacin 41 (100) 256 >256 8 (100) 128 128
Chloramphenicol 22 (53.6) 32 64 6 (75.0) 64 128
Rifampin 39 (95.2) 128 >256 6 (75.0) 8 64
Daptomycin 0 2 4 0 1 2
Quinupristin–dalfopristin 0 0.5 1 nd nd nd
R resistant;HLGR high-level gentamicin resistance;HLSR high-level streptomycin resistance; nd not determined;
a single isolate of E. avium was resistant to penicillin, ampicillin, streptomycin, tetracycline and erythromycin,
and had MIC values for linezolid = 16 ml/L and tedizolid = 4 mg/L
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was applied for all enterococcal isolates. The detection of vanA
and vanB was performed by polymerase chain reaction (PCR)
[10, 11], with E. faecium BM4147 and E. faecalis V583 as
positive controls, respectively. The Tn1546 structure was inves-
tigated by PCR mapping [12–17].
Molecular typing of isolates
The clonal relatedness of E. faecium and E. faecalis was in-
vestigated using multilocus sequence typing (MLST) [1, 3]
and the MLST database (http://pubmlst.org/; 1st February
2016, date last accessed). Sequence types (STs) were assigned
to CCs with comparative eBURST analysis against the whole
databases of E. faecium and E. faecalis (http://eburst.mlst.net/;
1st February 2016, date last accessed). E. faecium isolates
were additionally investigated using multiple locus variable-
number tandem repeat (VNTR) analysis (MLVA; http://www.
umcutrecht.nl/en/Research/Miscellaneous/MLVA-typing; 1st
August 2016, date last accessed).
Detection and analysis of linezolid resistance determinants
Isolates were examined for the presence of the G2576Tmutation
in the 23S rRNA genes by sequencing [18] and PCR-restriction
fragment length polymorphism (PCR-RFLP) analysis with NheI
[19] of individual copies of 23S rRNA genes of E. faecium and
E. faecalis (primer sequences available upon request). The rplC
and rplD genes encoding ribosomal proteins L3 and L4, respec-
tively, were sequenced [20] and compared to the wild-type se-
quences from E. faecalis ATCC 29212 (CP008816.1),
E. faecium DO (CP003583.1) and E. avium ATCC 14025
(ASWL01000001.1) strains. The cfr gene was searched for by
PCR [21] usingDNAof a cfr-positive clinical isolate of S. aureus
from the laboratory collection as a control (unpublished data) and
optrA and repBpE349 were detected by PCR with primers de-
signed in the study (5′-TCAACCTTGAAAGGGGACAG
/AGCCAAGAGCAGTTCTGACC-3 ′ and 5 ′-TGAA
TTAGCAGTCGCCAGTTTAG/TTACCGTTGGCAAA
TATTGTGTG-3′, respectively). The localisation of optrA was
established with pulsed-field gel electrophoresis (PFGE)-S1/
hybridisation analysis. To this end, total genomic DNAwas pu-
rified in agarose plugs [10], subjected to S1 nuclease digestion
(Takara Bio, Japan) and separated by PFGE [22], followed by
blotting onto the Hybond-N+ membrane (GE, Healthcare,
Buckinghamshire, UK) and hybridisation with the optrA probe,
using the Amersham ECL Random-Prime Labelling and
Detection System (GE Healthcare).
Conjugation experiments
Transferability of linezolid resistance was studied for the
optrA-positive isolates using a highly efficient conjugation
protocol [23] with E. faecalis OG1RF and E. faecium 64/3
as recipients.
Genomic sequencing and plasmidome of optrA–E. faecalis
Whole-genome sequencing (WGS) was performed with Ion
Torrent PGM (Thermo Fisher Scientific,Waltham,MA, USA)
or MiSeq (Illumina, San Diego, CA, USA) as an external
service. Obtained reads were assembled using the CLC
Genomic Workbench v.8 (CLC bio, Aarhus, Denmark) and
joining of contigs was performed with PCR (primer sequences
available upon request), followed by sequencing of the prod-
ucts. The presence of rep genes, unique and characteristic for
families 1–19, was either analysed by PCR [24] or deduced
from WGS data using the BLAST function in the CLC
software.
Growth experiments
The growth ratios of optrA transconjugants and recipient
strains as a measure of the bacterial fitness and plasmid cost
[25] were determined by culturing tested strains in BHI broth
with and without linezolid (8 mg/L) overnight, respectively,
diluting to OD 0.01 in BHI broth without antibiotics and
growing at 37 °C with shaking for 10 h. OD600 measurements
were taken every 30 min. The test was done twice, in three
biologically independent replicates. The number of colony-
forming units (CFUs) in cultures of recipients and
transconjugants from the beginning and end of the test (t0
and t10, respectively) was established by plating appropriate
dilutions on BHI agar and the enumeration of colonies.
Nucleotide accession numbers
The nucleotide sequence of rplD of E. avium, the complete
sequence of optrA-plasmid 1 from the KIEL E. faecalis isolate
and a partial sequence of plasmid 2 from the same isolate were
deposited in GenBank (accession numbers KX255697,
KY513280 and KY513281, respectively).
Results
Bacterial isolates: epidemiological data, species,
antimicrobial susceptibility and clonal relatedness
LRE were reported as single cases for 13 hospitals, while
seven hospitals, located in Warsaw, Wroclaw, Poznan and
Gdansk, sent up to 12 LRE each (Table 2, Supplementary
Fig. A1). The most prevalent species, E. faecium (41 isolates,
82%), occurred in 16 hospitals, while E. faecalis (8 isolates,
16%) was obtained in four centres. One isolate was identified
as E. avium. The first LRE was sent to the NRCST in
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September 2008, and, since 2012, the number of LRE per year
has been generally increasing, in parallel to the number of
affected hospitals (Table 2). Nearly half of the isolates were
obtained from colonised patients (21; 42%); 15 and 14 isolates
were from invasive and non-invasive infections, respectively.
Linezolid MIC values ranged from 8 to 128 mg/L and all
isolates were resistant to tedizolid (Table 1). All E. faecium
and E. faecalis isolates were resistant to ciprofloxacin, suscep-
tible to tigecycline and daptomycin and, in the case of
E. faecium, to quinupristin–dalfopristin. Additionally, all
E. faecium isolates displayed resistance to penicillin and am-
picillin. In both species, a high prevalence of high-level ami-
noglycoside resistance (HLAR) was observed. Vancomycin
resistance occurred only among E. faecium (37 isolates,
90.2%), mediated by the vanA and vanB gene clusters (34
and three isolates, respectively). All LRE exhibited the
MDR phenotype (resistance to three or more classes of anti-
microbials). Six E. faecalis isolates belonged to ST6, specific
for HiRECC 6, and the remaining two isolates represented
ST116 from CC116. Enterococcus faecium isolates represent-
ed eight related MLVA types (MTs) and 11 STs, characteristic
for nosocomial lineages 17/18 and 78 (Table 2). Typing of
Tn1546 of 20 vanA-positive E. faecium of MT12/ST117 from
seven centres identified three transposon variants, A, B and C
(Table 2).
Detection and analysis of linezolid resistance determinants
Sequencing of the 23S rRNA genes and the PCR-RFLP anal-
ysis of individual copies of 23S rDNA revealed the presence
of the G2576T mutation for 47 isolates (94%); the remaining
single isolate of E. faecium and two isolates of E. faecalis
harboured the wild-type 23S rRNA genes (Table 2). The num-
ber of mutated copies of the 23S rRNA gene ranged from one
to five out of six in E. faecium and from two to three out of
four in E. faecalis. All isolates harboured the wild-type rplC
gene. Mutation in the rplD gene was observed only for
E. avium, where the T511G substitution resulted in the
S171A change in the L4 deduced amino acid sequence.
None of the isolates carried the cfr gene. Initially, optrA was
detected in five isolates (10%), including two E. faecalis and
three E. faecium. In the case of the three latter isolates, the
gene was lost upon storage; thus, detailed analyses of optrA
localisation and transferability could be continued only for
E. faecalis. A remaining single isolate of E. faecium (linezolid
MIC=32 mg/L) did not contain any of the resistance determi-
nants studied. The PFGE-S1 analysis of optrA-positive
E. faecalis isolates showed the presence of two or three plas-
mids, ranging from <50 to ∼100 kb in size, and the subsequent
Southern blot analysis showed the localisation of optrA on a
plasmid below 50 kb in both cases. optrAwas transferable by
conjugation to both E. faecalis and E. faecium recipients.
Enterococcus faecium transconjugants harboured a single
plasmid of the size corresponding to the optrA plasmid from
clinical isolates, while in E. faecalis transconjugants, either
the optrA plasmid was accompanied by another plasmid, also
below 50 kb in size, or a single ∼100-kb plasmid was ob-
served. WGS of an optrA–E. faecalis transconjugant (donor:
isolate from 2013 from a BYD hospital) with a ∼100-kb pre-
sumably recombinant plasmid yielded five contigs (sequenc-
ing coverage 86–140×), absent from the OG1RF genomic
sequences (accession no. NC_017316). Two of these contigs
were successfully joined by PCR into a 36,331-bp contig,
100% identical to the corresponding part of the conjugative
plasmid pE349 carrying optrA (accession no. KP399637) [8]
and characterised by the presence of the unique repBpE349
gene. The remaining three contigs showed a partial homology
to the region encompassing 1.2–41.6 kb of the pTEF2 plasmid
(accession no. AE016831; data not shown). In the donor iso-
late, PCR analysis revealed the presence of rep9 and rep17
genes. In growth experiments, an optrA–E. faecium
transconjugant was characterised by a significantly delayed
Fig. 1 Growth curves of
Enterococcus faecalis OG1RF
and Enterococcus faecium 64/3
and their optrA transconjugants
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entrance into the logarithmic phase of growth, compared to
the E. faecium 64/3 recipient, as well as to an optrA–
E. faecalis transconjugant and the E. faecalis OG1RF recipi-
ent (Fig. 1). WGS of the other optrA clinical isolate (obtained
in 2012 in a KIEL hospital) demonstrated that two contigs
(35,000 bp and 1526 bp, coverage 178× and 329×, respective-
ly) had sequences identical to pE349. These two contigs were
successfully joined by PCR and sequencing of the products
into a single circular plasmid, 36,331 bp in size
(Supplementary Fig. 2A). This plasmid was also transferable
by conjugation to both E. faecalis and E. faecium. The
BLAST analyses of genomic sequences of the KIEL
E. faecalis isolate revealed solely the presence of a represen-
tative of rep9 family, with the highest homology (94.0–
96.6%) to prgW from pBEE99 (GU046453; [26]) and to
repA genes of pMG2200 (AB374546; [27]) and pTEF2
(AE016831; [28]). This gene was located in a 20,525-bp
contig (coverage 105×). This contig, presumably representing
a part of a plasmid, showed similarity to pheromone-
responsive plasmids, such as pBEE99 and to some Gram(+)
integrative-conjugative elements, such as Tn6248
(KP834592), found in a pig isolate of E. faecium in China
(Supplementary Fig. 2B).
Discussion
Linezolid is an important agent in the treatment of serious
infections caused bymultidrug-resistant Gram-positive organ-
isms, including methicillin-resistant S. aureus (MRSA) and
VRE. The first case of LRE in Poland occurred in
July 2003, shortly after the introduction of linezolid for treat-
ment in our country in February 2002 [29]. Although LRE
remain relatively rare in Poland [30], their increasing number
is reported to the NRCST, along with a growing number of
affected hospitals. While in systematic surveillance a stable
low prevalence of linezolid resistance in Gram-positive bac-
teria, including enterococci, is observed [7], some other stud-
ies show a local increase of LRE, e.g. in Germany [31], similar
to the situation observed in Poland. In our study, over 70% of
LREwere isolated from patients of intensive care units (ICUs)
and haematology wards, which are wards with the highest use
of antimicrobials, including linezolid. LRE occurredmostly as
sporadic cases, in agreement with the previous observations
about the nature of LRE emergence [32]. Nevertheless, in
some centres, the epidemic spread of LRE was observed, as
indicated by a similar time of isolation, the same genotype and
mechanism of resistance. Linezolid resistance was identified
almost exclusively in two enterococcal species, which are the
most frequent causes of enterococcal HAIs, E. faecalis and
E. faecium. The linezolid-resistant E. faecium showed much
higher prevalence of vancomycin resistance (90.2%), than
typically found in HAIs in Polish hospitals for this species
(7.1%) [30]. The analysis of clonality, resistance determinants
and the Tn1546 structure indicated possible VRE/LRE out-
breaks and even presumable transfer(s) among hospitals. The
combination of these two resistance phenotypes in the back-
ground of multiresistant epidemic hospital meroclone is espe-
cially worrisome due to the lack of effective treatment options,
and highlights the importance of active surveillance and infec-
tion control procedures.
The G2576T mutation within the domain Vof 23S rRNA
was the most frequent mechanism of linezolid resistance de-
veloped by Polish LRE, as frequently reported for enterococ-
cal clinical isolates [7]. None of the isolates, however,
harboured the G2576T mutation in all copies of 23S rDNA,
which indicates that lack of the wild-type copy might impose
too big a fitness cost for the cell [33]. The second mutational
mechanism of resistance, was the T511G mutation in rplD
(the S171A substitution in the L4 ribosomal protein) identified
in our study for E. avium. The S/P mutation at the same posi-
tion in a clinical E. avium isolate also from Poland constituted
the only mechanism responsible for its elevated MIC of linez-
olid [7]. The only non-mutational mechanism of linezolid re-
sistance detected in our study was the presence of ABC trans-
porter OptrA [8]. Another linezolid resistance determinant,
cfr, was not found, although its presence was observed for
both E. faecalis and E. faecium [20, 34]. The optrA gene
was first identified on the pE349 plasmid [8] and detected in
human and animal E. faecalis and E. faecium from China,
Malaysia, Austria, Ireland and Italy [8, 35–37]. In our study,
the optrA gene was the only determinant of linezolid resis-
tance detected in two epidemiologically unrelated non-
HiRECC E. faecalis of ST116. We also observed a loss of this
determinant from three isolates of E. faecium, which addition-
ally carried the G2576T mutation. A loss of conjugative resis-
tance plasmids was reported by others [25]. Such instability
might explain the generally much lower prevalence of optrA
in E. faecium compared to E. faecalis [8, 38], and would be in
agreement with the fitness cost imposed by an optrA plasmid
on E. faecium transconjugant, observed in this study. The
optrA-carrying plasmid was transferable from E. faecalis to
both E. faecium and E. faecalis recipients, alone or with a
second plasmid, respectively. The optrA plasmids of
E. faecalis characterised so far are typically conjugative [8].
It is tempting to speculate about a possible source of the optrA
gene, located on pE349, for clinical enterococci in Poland. As
previously suggested, E. faecalis ST116, characteristic for
isolates from both human infections as well as food-
producing animals and retail meat [8, 39], may act as a vehicle
of antimicrobial resistance between environment and hospital,
similarly to vancomycin-resistant E. faecalis from imported
turkey meat and clinical isolate, which also shared this ST
[39]. Moreover, three isolates of E. faecalis from poultry, car-
rying pE349-like plasmids with the optrA gene, were reported
recently from Columbia [40], indicating a global spread of
Eur J Clin Microbiol Infect Dis
optrA plasmids and supporting the potential role of an animal
reservoir. Thus, a food-borne E. faecalis with pE349 could
serve as a potential source of optrA for nosocomial enterococ-
ci, raising a new aspect for food safety.
In conclusion, we performed an extensive analysis of
linezolid- and tedizolid-resistant isolates of Enterococcus
spp., obtained recently from carriage and HAIs in Polish hos-
pitals. The emergence of LRE was predominantly caused by
independent de novo resistance development in various en-
terococcal strains, mostly representing HiRECCs, for which
acquisition of linezolid resistance may be a next step in their
evolution as hospital ‘superbugs’. While the mutation within
the 23S rRNA gene was the most common determinant of
resistance, the detection of the multiresistance gene optrA
among Polish LRE and evidence for its in vitro transferability
raises further concerns about the possible decreasing effective-
ness of linezolid treatment in the future.
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